Aindo SpA
Aindo's mission is to make health data usable for better evidence, decisions, and innovation. It builds generative-AI synthetic-data and AI evidence infrastructure that lets organizations use sensitive data for research, AI development, and decision-making while protecting privacy, fairness, and compliance.
At a Glance
- Pharmaceutical and life-sciences companies
- Contract research organizations (CROs)
- Hospitals, researchers, and clinicians
- Public healthcare systems and administrations
- +2 more
AI Tools by Aindo SpA
(1)
Aindo
Synthetic Data for Healthcare
Discussions
No discussions yet
Be the first to start a discussion about Aindo SpA
Latest News
Aindo officially joins AICROplus to integrate AI and synthetic data into clinical research.
Aindo continues its sustainability program through collaboration with Green Future Project and BizAway.
Aindo and IQVIA Italy sign a three-year strategic partnership to accelerate synthetic health data adoption.
Aindo wins €2.1 million EIC Accelerator research funding for synthetic-data innovation.
Products & Services
Generative-AI platform that creates high-fidelity synthetic structured, tabular, and relational data for privacy-safe analysis, model development, sharing, and evidence generation.
Healthcare offering for pharmaceutical companies, CROs, and research organizations to generate analysis-ready synthetic datasets for regulatory submissions, post-market surveillance, comparative effectiveness, health economics, feasibility, and cross-site collaboration.
Synthetic cohorts/external control arms for single-arm and rare-disease studies, comparative-effectiveness analysis, reduced placebo exposure, and faster clinical-trial evidence generation.
Specialized healthcare language-model offering for clinical documentation and summarization, medical knowledge retrieval, research and protocol support, data exploration, and internal operational copilots.
Market Position
Aindo positions itself as a European, privacy-first synthetic-data and AI evidence-infrastructure provider focused especially on healthcare and other regulated sectors. Its differentiation is the combination of generative synthetic data, relational-data capabilities, real-world-evidence and synthetic-control-arm workflows, local deployment, and healthcare-specific compliance validation including Europrivacy certification.
Leadership
Founders
Daniele Panfilo
PhD researcher in AI generative models and machine learning; previously trained in industrial engineering at Sapienza University of Rome and AI at Maastricht University. Chief Executive Officer and co-founder of Aindo.
Sebastiano Saccani
PhD in physics/theory and numerical simulation of condensed matter from SISSA, with a background in applied AI/ML and enterprise applications. Chief Product and R&D and co-founder of Aindo.
Borut Svara
AI expert and software/infrastructure engineer; served as Aindo's founding Chief Technology Officer, leading development of its synthetic-data and generative-AI platform.
Executive Team
Daniele Panfilo
Chief Executive Officer, Co-Founder
PhD AI/generative-model scientist and entrepreneur; previously trained in industrial engineering and AI.
Sebastiano Saccani
Chief Product and R&D, Co-Founder
PhD physicist from SISSA with applied AI/ML and simulation expertise.
Founding Story
Aindo was founded at SISSA (International School for Advanced Studies) in Trieste in 2018 as a boutique AI consulting lab. The founders wanted to make sensitive data safely usable for innovation by combining generative AI with privacy-preserving technologies; the initial focus was healthcare and finance, later expanding into AI evidence infrastructure for regulated sectors.
Business Model
Revenue Model
Enterprise sales of synthetic-data and AI evidence infrastructure, typically delivered as a platform/service engagement and supported by consulting, implementation, and partnership work. The platform is offered for organizational data and can be deployed locally; public pricing is not listed.
Target Markets
- Pharmaceutical and life-sciences companies
- Contract research organizations (CROs)
- Hospitals, researchers, and clinicians
- Public healthcare systems and administrations
- Finance, banking, and insurance companies
- Organizations developing AI/ML in regulated or privacy-sensitive environments
- Real-world evidence generation
- Clinical trials and synthetic external control arms
- Healthcare and life-sciences research
- Clinical workflow intelligence and medical knowledge retrieval
- Training and testing machine-learning models without processing personal data
- Data sharing and multi-site or cross-border collaboration
- BeRebel
- IQVIA Italy